VERTEX PHARMACEUTICALS INC (VRTX) Cash flow
Market cap
$111.4B
P/E ratio
28.6x
| 2010/12 | 2011/12 | 2012/12 | 2013/12 | 2014/12 | 2015/12 | 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | 2025/12 | |
| Depreciation & amortization | 30 | 35 | 38 | 48 | 63 | 62 | 61 | 61 | 72 | 107 | 110 | 126 | 148 | 181 | 207 | 210 |
| Stock-based compensation | 91 | 118 | 114 | 127 | 178 | 231 | 238 | 291 | 325 | 360 | 429 | 441 | 491 | 581 | 699 | 686 |
| Cash from operations | -635 | 144 | 268 | -52 | -513 | -365 | 236 | 845 | 1,270 | 1,569 | 3,254 | 2,644 | 4,130 | 3,537 | -493 | 3,631 |
| Capital expenditures | -38 | -35 | -71 | -51 | -51 | -45 | -57 | -99 | -96 | -75 | -260 | -235 | -205 | -200 | -298 | -438 |
| Cash from investing | 7 | 212 | -426 | -54 | 74 | 269 | 104 | -438 | -202 | -1,235 | 99 | -341 | -321 | -3,142 | -3,770 | -945 |
| Repurchases of common stock | - | - | - | - | - | - | - | - | 350 | 192 | 539 | 1,425 | - | 428 | 1,177 | 2,017 |
| Proceeds from issuance of term debt, net | 392 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cash from financing | 425 | -124 | 172 | 181 | 497 | 189 | 133 | 68 | -71 | 127 | -505 | -1,478 | -68 | -562 | -1,495 | -2,261 |
| Free cash flow | ||||||||||||||||
| FCF margin (%) |